DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Consensus

—

Average target

$16.00

Implied upside

—

Analysts

—

Why Is DRIO Down 22.35% Today?

DarioHealth Corp. reported Q3 2026 financial results that included mixed performance—beating revenue estimates while posting a net loss. The significant stock decline suggests market disappointment with profitability metrics or forward guidance, despite operational improvements on the revenue and expense fronts.

Bottom line: While DarioHealth delivered mixed Q3 results with beats on both revenue and adjusted earnings, the company's continued GAAP net loss appears to have spooked investors, triggering a sharp 22% sell-off. Investors should monitor whether management provides clearer guidance on the timeline to profitability and whether the positive operational trends (expense reduction + revenue growth) can accelerate the path to sustainable earnings.